Intelligent bio solutions successfully completes recruitment and begins subject screening for fda 510(k) pharmacokinetic (pk) study

New york, may 29, 2024 (globe newswire) -- intelligent bio solutions inc. (nasdaq: inbs) ("inbs" or the "company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful recruitment and commencement of screening for subjects in its pharmacokinetic (pk) study, a critical component of the company's fda 510(k) regulatory pathway for clearance.
INBS Ratings Summary
INBS Quant Ranking